Introduction
Glycogen-synthase kinase-3 (GSK-3) has been implicated in multiple biological processes including embryonic development, cell differentiation, apoptosis and insulin response (Frame and Cohen, 2001; Jope and Johnson, 2004) . Two isoforms of GSK-3, GSK-3a and GSK-3b, have been identified with high homology and similar but not identical biochemical properties (Doble and Woodgett, 2003) . Activation of phosphatidylinositol 3-kinase (PI3-kinase) results in the phosphorylation and activation of Akt (King et al., 1997) . Akt activation results in GSK-3 inhibition by phosphorylation of Ser21 in GSK-3a and Ser9 in GSK-3b (Jope and Johnson, 2004) . GSK-3 regulates the phosphorylation status of a broad range of substrates (Ali et al., 2001; Frame and Cohen, 2001 ). For example, in its active state (i.e., unphosphorylated state), GSK-3 increases cell adhesion through the phosphorylation of b-catenin and MUC1 (Li et al., 1998; Frame and Cohen, 2001) . GSK-3 is involved in cell cycle regulation through the phosphorylation of cyclin D1, which results in the rapid proteolytic turnover of cyclin D1 protein (Diehl et al., 1998; Frame and Cohen, 2001 ). In addition, GSK-3 phosphorylates several transcription factors, such as c-Myc, c-Jun and c-Myb and the translation factor eIF2B (Plyte et al., 1992; Frame and Cohen, 2001) . Recently, we reported the inhibition of PI3-kinase, which results in GSK-3 activation, enhances intestinal epithelial cell differentiation . Consistent with its position downstream of the PI3-kinase pathway, GSK-3 activity suppresses cell proliferation and survival in certain cells (Frame and Cohen, 2001; Mazor et al., 2004) . However, the downstream targets of PI3-kinase and the crosstalk with other signal pathways involved in intestinal differentiation and proliferation are unknown.
Mitogen-activated protein kinases (MAPKs) are serine-threonine kinases that are activated by phosphorylation in response to a wide array of extracellular stimuli (Seger and Krebs, 1995; Schaeffer and Weber, 1999) . Three distinct groups of MAPKs have been identified in mammalian cells (i.e., extracellular signalregulated kinase (ERK), JNK, and p38), which play important roles in diverse cellular processes (Seger and Krebs, 1995; Schaeffer and Weber, 1999) . The ERKs (ERK1 and ERK2) are activated by MEK and are generally thought to regulate cell growth and differentiation, whereas JNK and p38 are considered the stress-activated MAPKs and regulate cellular apoptosis and response to stress (Minden and Karin, 1997) . We have found that inhibition of MEK/ERK enhances intestinal cell differentiation (Ding et al., 2001) .
Recently, GSK-3 has been shown to induce activation of the mitogen-activated protein kinase kinase kinase, MEKK1, an activator of JNK, and thereby to promote signaling by the stress-activated protein kinase pathway (Kim et al., 2003) . MEK-1/2 is involved in the phosphorylation of Ty216 in GSK-3, which increases GSK-3 activity, in human skin fibroblasts (TakahashiYanaga et al., 2004) . However, the potential actions of GSK-3 in regulating MAPK/ERK have not been described.
In our current study, we investigated the possible regulation of ERK1/2 by GSK-3 in human intestinal cells. Here, we show that inhibition of GSK-3 significantly induced the phosphorylation of ERK1/2. Inhibition of PKCd or transfection with PKCd siRNA attenuated ERK1/2 phosphorylation induced by GSK-3 inhibition. Expression and promoter activity of cyclooxygenase-2 (COX-2) and IL-8, two downstream targets of ERK1/2 activation, was increased by GSK-3 inhibition; this induction was abolished by MEK inhibition, suggesting GSK-3 inhibition induced COX-2 and IL-8 through MAPK/ERK1/2 activation. These results suggest that GSK-3 functions as a natural negative regulator of MAPK/ERK1/2. Moreover, our findings identify a novel mechanism whereby GSK-3 function can regulate the phosphorylation status of ERK1/2 in intestinal cells and, therefore, alter downstream gene expression.
Results

Inhibition of GSK-3 increases the phosphorylation of ERK1/2
We have found that inhibition of PI3-kinase or MEK/ ERK enhances intestinal epithelial cell differentiation (Ding et al., 2001; Wang et al., 2001) . To investigate the possible regulatory effect of GSK-3 on the MEK/ERK signaling pathway, HT29 cells were incubated in serumfree medium for 24 h followed by treatment with the GSK-3 inhibitors, LiCl, a potent GSK-3 inhibitor (Phiel and Klein, 2001) , or SB-216763 and SB-415286. SB-216763 and SB-415286 are structurally distinct maleimides that are potent and specific inhibitors of GSK-3a and b in an ATP competitive manner at the dosages used in this study (Coghlan et al., 2000; Eickholt et al., 2002) . Treatment with SB-216763, SB-415286 and LiCl increased ERK1/2 phosphorylation without altering ERK1/2 protein levels ( Figure 1a , left). To determine whether the effect of GSK-3 inhibition was specific to HT29 cells or occurs in other cell lines, Caco-2, 293 or PC-3 cells were incubated in serum-free medium for 24 h and then treated with GSK-3 inhibitors. Similar to HT29, treatment with the GSK-3 inhibitors induced ERK1/2 phosphorylation in another human colon cancer (Caco-2), as well as, human embryonic kidney cell line (293) and human prostate Figure 1 GSK-3 inhibition induces phosphorylation of ERK1/2 in HT29 cells. (a) HT29, Caco-2, 293 or PC-3 cells were starved in serum-free medium for 24 h followed by treatment with the GSK-3 inhibitor SB-216763 (10 mM), SB-415286 (30 mM), LiCl (20 mM) or vehicle control DMSO for 30 min and whole-cell protein extracted for p-ERK1/2 and total ERK1/2 expression by Western blot. (b) HT29 cells were starved in serum-free medium for 8 h followed by treatment with various concentrations of SB-216763 for 30 min and whole-cell protein extracted for p-ERK1/2 and total ERK1/2 expression by Western blot. (c) HT29 cells were starved in serum-free medium for 24 h followed by treatment with SB-216763 (10 mM) for various times and whole-cell protein extracted for p-ERK1/2 and total ERK1/2 expression by Western blot. (d) HT29 cells were starved in serum-free medium for 24 h. Cells were pretreated with the MEK-1 inhibitor U0126 or PD98059 for 30 min followed by combination treatment with GSK-3 inhibitor SB-216763 (10 mM) or vehicle control DMSO for an additional 30 min and whole-cell protein extracted for p-ERK1/2 and total ERK1/2 expression by Western blot. (e) HT29 cells were transfected with GSK-3a, GSK-3b or control siRNA. After a 48 h incubation, transfected cells were harvested and whole-cell protein extracted for phosphorylation levels of ERK1/2 by Western blot using anti-p-ERK1/2 antibody; blots were stripped and reprobed with anti-ERK antibody (left). To confirm GSK-3 suppression, GSK-3a and GSK-3b expression was assessed by Western blot using anti-GSK-3a/b antibody; blots were stripped and reprobed with antiactin antibody (right). Representative data from three separate experiments are shown here.
Activation of ERK by GSK-3 inhibition Q Wang et al cancer cell line (PC-3) (Figure 1a , right). Treatment with SB-216763 induced ERK phosphorylation in a dose-dependent fashion with p-ERK1/2 induction noted using a dosage of only 2.5 mM (Figure 1b ). To next assess the time course for ERK phosphorylation, HT29 cells were treated with SB-203580 (10 mM) for 10 min-8 h ( Figure 1c ). Induction of ERK phosphorylation was noted at all time points. To determine whether the ERK phosphorylation was MEK-1 dependent, cells were pretreated with MEK-1 inhibitor (either U0126 or PD98059), which dose-dependently blocked the induction of ERK phosphorylation ( Figure 1d ). Taken together, these results suggest that GSK-3 inhibition induces ERK1/2 phosphorylation, thereby triggering ERK1/2 activation. To further demonstrate the regulation of the MEK/ ERK pathway by GSK-3, we used siRNA directed to either GSK-3a or GSK-3b to suppress GSK-3a and GSK-3b expression, respectively. The suppression of GSK-3 induced ERK1/2 phosphorylation in HT29 cells as compared to cells transfected with control siRNA (Figure 1e , left). Immunoblotting analysis confirmed that expression of GSK-3a or GSK-3b was significantly inhibited by GSK-3a and GSK-3b siRNA, respectively (Figure 1e, right) . Together, our data indicate that GSK-3a and GSK-3b are important regulators of ERK1/2.
GSK-3 inhibition induces phosphorylation of ERK1/2 through PKCd activation Next, we investigated the signaling mechanisms responsible for ERK regulation by GSK-3. Since PKCd has been implicated as an activator of MEK/ERK in certain cell lines (Miranti et al., 1999; Lee et al., 2002) , we used rottlerin, a selective PKCd inhibitor (Wang et al., 2003; Murugappan et al., 2004) , to assess the potential role of PKCd in GSK-3 inhibition-induced ERK1/2 phosphorylation. Pretreatment with rottlerin attenuated ERK1/2 phosphorylation induced by the GSK-3 inhibitor, SB-216763 (Figure 2a , left). Activation of PKCd by SB-216763 was also demonstrated by the increased phosphorylation of myelin basic protein (MBP) after SB-216763 treatment (Figure 2a, right) . The attenuation of SB-216763-induced ERK1/2 phosphorylation by rottlerin and the increase of PKCd activity by treatment with SB-216763 suggest that PKCd may play a role in Figure 2 PKCd activity is required in the phosphorylation of ERK1/2 by GSK-3 inhibition in HT29 cells. (a) Left: HT29 cells were starved in serum-free medium for 24 h. Cells were pretreated with rottlerin for 30 min followed by treatment with the GSK-3 inhibitor SB-216763 (10 mM) for 30 min and whole-cell protein extracted for p-ERK1/2 and total ERK1/2 expression by Western blot. Right: HT29 cells were starved in serum-free medium for 24 h followed by treatment with SB-216763 (10 mM) for 30 min. Whole-cell protein was prepared from control or SB-216763 treated cells followed by immunoprecipitation of PKCd and PKCd activity measured using MBP as substrate. (b) HT29 cells transfected with control or PKCd siRNA were starved in serum-free medium for 24 h. Cells were treated with SB-216763 (10 mM) for 30 min and whole-cell protein extracted for p-ERK1/2 and total ERK1/2 (left) or PKCd, PKCa, actin (right) expression by Western blot. (c) HT29 cells were transfected with control or GSK-3a and GSK-3b siRNA. After 24 h incubation, transfected cells were harvested and whole-cell protein extracted for p-ERK1/2, total ERK1/2, GSK-3a and GSK-3b expression by Western blot and PKCd activity by kinase assay using MBP as substrate. Representative data from three separate experiments are shown here.
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To confirm the role of PKCd in ERK1/2 phosphorylation mediated by GSK-3 inhibition, HT29 cells were transfected with control siRNA or siRNA targeting the PKCd gene for 24 h followed by serum starvation for an additional 24 h. Cells were treated with vehicle (i.e., DMSO) or SB-216763 for 30 min. Transfection with the PKCd siRNA suppressed ERK1/2 phosphorylation induced by SB-216763 treatment (Figure 2b, left) . Expression of endogenous PKCd was decreased without affecting PKCa and actin expression, confirming that the siRNA-directed PKCd specifically decreases PKCd expression (Figure 2b, right) .
To further establish the role of PKCd in ERK1/2 phosphorylation by GSK-3 inhibition, HT29 cells were transfected with control siRNA or a combination of the siRNA targeting GSK-3a and the siRNA targeting GSK-3b for 24 h. As shown in Figure 2c , transfection with both siRNAs not only induced ERK1/2 phosphorylation but also increased PKCd activity as demonstrated by increased phosphorylation of MBP utilizing an in vitro kinase assay (bottom panel). Taken together, these results demonstrate a contributory role for PKCd in the negative regulation of ERK by GSK-3 in human colon cancer cells.
GSK-3 inhibition increases COX-2 and IL-8 expression in an MEK/ERK-dependent manner
We next determined the effect of GSK-3 inhibition on the downstream gene targets COX-2 and IL-8. Previous studies have shown that inhibition of GSK-3 induces COX-2 expression in certain cells (Tang et al., 2001; Rao et al., 2004) . The effect of GSK-3 inhibitors on COX-2 expression was determined using SB-216763, SB-415286 or LiCl in HT29 cells. All three inhibitors increased COX-2 mRNA expression (Figure 3a) . To identify whether MEK/ERK was required for COX-2 induction by GSK-3 inhibitors, HT29 cells were pretreated with U0126, an inhibitor of MEK-1/2, for 30 min before treatment with GSK-3 inhibitors for 4 h. Treatment with U0126 blocked induction of COX-2 mRNA by GSK-3 inhibition. To determine whether GSK-3 inhibition results in COX-2 promoter induction, HT29 cells were transfected with the human COX-2 promoter (À1432/ þ 59) linked to the luciferase reporter gene (Inoue et al., 1994) and then treated with either SB-216763 or cotransfected with GSK-3a or GSK-3b siRNA. GSK-3 inhibition significantly increased COX-2 promoter activity in SB-216763-treated HT29 cells (Figure 3b, left) . Negative regulation of COX-2 by GSK-3 was further confirmed by increased COX-2 promoter activity noted with co-transfection of either GSK-3a or GSK-3b siRNA (Figure 3b, right) .
The MEK/ERK1/2 pathway plays an important role in the induction of IL-8 in HT29 cells (Remacle-Bonnet et al., 2000; Akhtar et al., 2003) . Since GSK-3 inhibition induces ERK1/2 phosphorylation, we next examined whether GSK-3 inhibition also induces IL-8 expression. HT29 cells were incubated in serum free medium for 24 h followed by treatment with GSK-3 inhibitors, SB-216763, SB-415286 or LiCl, for 4 h. All of the GSK-3 inhibitors induced IL-8 mRNA expression in HT29 cells (Figure 3c) . A 30 min pretreatment of HT29 cells with the MEK/ERK inhibitor U0126 resulted in a Figure 3 MEK/ERK1/2 is required for GSK-3 inhibition induced COX-2 and IL-8 expression. (a) HT29 cells were starved in serumfree medium for 24 h followed by pretreatment with or without the MEK inhibitor U0126 (10 mM) for 30 min and then treated with LiCl (20 mM), SB-216763 (10 mM), or SB-415286 (30 mM) alone or in combination for 4 h. RNA was isolated and analysed by Northern blotting. (b) HT29 cells were transfected with a plasmid containing the human COX-2 promoter fragment linked to the luciferase reporter or empty vector. After 24 h incubation, the transfected cells were treated with SB-216763 (10 mM) for an additional 24 h (left) or cotransfected. with GSK-3a, GSK-3b or control siRNA. After 48 h incubation, cells were harvested and luciferase activity measured in the crude cell lysates as described in 'Materials and methods'. All results were normalized for transfection efficiency using the pRL-Tk-luc plasmid (Promega). (c) HT29 cells were starved in serum-free medium for 24 h followed by pretreatment with or without the MEK inhibitor U0126 (10 mM) for 30 min and then treated with LiCl (20 mM), SB-216763 (10 mM), or SB-415286 (30 mM) alone or in combination for 4 h. Total RNA was isolated and IL-8 mRNA expression analyzed by RNase protection assay using the hCK-5 multi-probe (Pharmingen). The probe set includes cDNAs for L32 and GAPDH to control for RNA loading. (d) HT29 cells were transfected with a plasmid containing the human IL-8 promoter fragment linked to the luciferase reporter or empty vector. After 24 h incubation, the transfected cells were treated with SB-216763 (10 mM) for an additional 24 h and cells were harvested and luciferase activity measured in the crude cell lysates as described in 'Materials and methods' section. Representative data from three separate experiments are shown here.
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Q Wang et al marked decrease in the induction of IL-8 expression by GSK-3 inhibition. The transcriptional induction of IL-8 by GSK-3 inhibition was also demonstrated by increased IL-8 promoter activity after SB-216763 treatment (Figure 3d ). Therefore, GSK-3 inhibition induces IL-8 expression and this induction is blocked by MEK/ERK inhibition. Collectively, our results indicate that GSK-3a/b is an important regulator of ERK1/2 and mediates ERK1/2-dependent regulation of COX-2 and IL-8 induction.
Discussion
The PI3-kinase/Akt and Ras/Raf/MEK pathways regulate diverse cellular processes including cell growth, survival and differentiation (Schaeffer and Weber, 1999; Wilkinson and Millar, 2000; Ding et al., 2001; Vanhaesebroeck et al., 2001; Wang et al., 2001 ). Previously, we have shown that inhibition of PI3-kinase, by chemical inhibition or PTEN overexpression, or the inhibition of MAPK/ERK enhances differentiation and apoptosis of colon cancer cell lines (Ding et al., 2001; Wang et al., 2001) . Here, we show that GSK-3 inhibition, acting through PKCd, induces ERK phosphorylation and subsequent induction of downstream effectors, COX-2 and IL-8. These findings identify a novel crosstalk mechanism involving the inhibition of GSK-3 regulating ERK activation. Our studies demonstrate that inhibition of GSK-3 induces ERK phosphorylation. Recently, it was reported that GSK-3b physically associates with and activates MEKK1, thereby stimulating the JNK/SAPK pathway (Kim et al., 2003) , which is consistent with the findings that PI3-kinase and Akt act as negative regulators of the JNK/SAPK cascade (Park et al., 2002; Aikin et al., 2004) . Other studies have suggested an inverse regulation of JNK/SAPK and MEK/ERK in various cellular processes such as apoptosis (Pan et al., 2002; Wang et al., 2004) . Consistent with these studies, we have shown that ERK activity was decreased in HT29 cells treated with the differentiating agent sodium butyrate and, in contrast, JNK1 activity and c-Jun phosphorylation was increased (Ding et al., 2001) . Treatment with sodium butyrate increased GSK-3 activity in HT29 cells accompanied by the induction of apoptosis, which was attenuated by pretreatment with the GSK-3 inhibitor LiCl (QD Wang, unpublished data). GSK-3b is tyrosine-phosphorylated by MEK-1 in human skin fibroblasts (Takahashi-Yanaga et al., 2004) . Together, these findings suggest the existence of a feedback loop between GSK-3b and MEK/ERK. In contrast, a recent report has shown that deletion of GSK-3b abolished TNF-induced ERK1/2 activation and the expression of the NF-kB-regulated gene products cyclin D1, COX-2, MMP-9 in fibroblasts derived from GSK-3b gene-deleted mice (Takada et al., 2004) . These differences may be due to different cell types or the differentiation status of the cells. For example, inhibition of GSK-3 by LiCl decreases p21 waf1 induction in human neuroblastoma (Watcharasit et al., 2002) , but increases p21 waf1 expression in human umbilical vein endothelial cells (Rossig et al., 2002) . Enforced activation of Akt, which phosphorylates Raf-1 on Ser-259 and results in a decrease in Raf-1 activity (Zimmermann and Moelling, 1999) , or inhibition of the MEK-ERK pathway in C2C12 cells promoted differentiation and myotube formation, whereas enforced Raf-1 activity blocked differentiation in the precursor myoblast stage. The crosstalk was only observed in postdifferentiation myotubes and not in myoblasts, where Akt activity or its inhibition had no influence on the Ras-Raf-MEK-ERK pathway (Rommel et al., 1999) .
Our results clearly show that inhibition or silencing PKCd attenuates ERK phosphorylation induced by GSK-3 inhibition. PKCd, a novel member of the PKC family, has been associated with apoptosis, cell transformation, growth arrest and differentiation of various cell types (Perletti et al., 1999; Brodie and Blumberg, 2003) . For example, we have demonstrated a role for a PKCd/NF-kB-dependent pathway in the regulation of cIAP-2 expression in human colon cancer cells (Wang et al., 2003) . Another report demonstrated that IGF-1 increases cIAP-2 expression through Akt activation in multiple myeloma cells (Mitsiades et al., 2002) . It is possible that GSK-3 inhibition may play a role in the induction of cIAP-2 by IGF treatment. Previous reports have shown that PKCd phosphorylates and activates ERK in certain cells (Miranti et al., 1999; Lee et al., 2002) and PKCd activates ERK either downstream from or in parallel with c-Raf, but upstream of MEK (Corbit et al., 1999) . In the present study, we have shown that inhibition of PKCd can block GSK-3 inhibitor-induced activation of ERK. To determine whether PKCddependent ERK phosphorylation is through MEK-1, we blocked MEK-1 activation by the MEK-1 inhibitors U0126 or PD98059. Both inhibitors blocked GSK-3 inhibitor-induced ERK phosphorylation suggesting that the PKCd/MEK pathway is involved in ERK phosphorylation. Although we noted a partial colocalization of PKCd and GSK-3b in HT29 cells and inhibition of GSK-3 increased PKCd activity, we failed to detect a direct binding between these two kinases by immunoprecipitation assay (data not shown). Interestingly, recent reports have shown a weak phosphorylation by an in vitro kinase assay (Fang et al., 2002) and inactivation of GSK-3 by PKCd in human neuroblastoma cells (Tsujio et al., 2000) . Further studies are needed to delineate the mechanisms involved in the activation of PKCd by GSK-3 inhibition in intestinal cells.
COX-2, the rate-limiting enzyme for prostaglandin synthesis, plays a critical role in the inflammatory response and in colon tumorigenesis (Williams et al., 1999; Claria, 2003) . COX-2 is induced in number of cells, including HT29, through activation of ERK (Chen et al., 2004; Tominaga et al., 2004) . We next evaluated downstream targets for ERK and found that inhibition of GSK-3 induced COX-2 expression in HT29 cells. These results are in agreement with those of other investigators showing activation of NF-kB, through the inhibition of GSK-3, increased COX-2 expression and promoter activity, while GSK-3b overexpression reduced COX-2 reporter activity in renal medullary interstitial cells (Rao et al., 2004) . The role of GSK-3 in the regulation of COX-2 expression was also reported in ultraviolet-induced COX-2 expression in HaCaT cells (Tang et al., 2001) . In addition to COX-2, we found that inhibition of GSK-3-induced IL-8 expression in HT29 cells. IL-8, a potent chemotactic factor, has been implicated in the pathogenesis of several gastrointestinal inflammatory states (Papadakis and Targan, 2000) and in the growth of colon cancers as an autocrine growth factor (Brew et al., 2000) . The expression of IL-8 is regulated by ERK/NF-kB activation in human head and neck squamous cell carcinomas (Bancroft et al., 2001) and colonocytes (Zhao et al., 2001) . Although inhibition of GSK-3 increases IL-8 expression and secretion in certain cells by increased nuclear translocation of b-catenin (Levy et al., 2002; Choi et al., 2004) , it may not be the case in our study since b-catenin or APC are mutated in colorectal cancers (Morin et al., 1997) and in colon cancer cell lines, such as HT29 and Caco-2 cells (Ilyas et al., 1997) . As a result, the mutation of bcatenin or APC results in b-catenin resistance to GSK-3-induced phosphorylation (Wong and Pignatelli, 2002) . Indeed, we did not detect any effect of GSK-3 inhibition on the subcellular distribution or expression of b-catenin in HT29 cells (QD Wang, unpublished observations) . In contrast to the b-catenin pathway, we found that inhibition of GSK-3-induced COX-2 and IL-8 expression; this induction was attenuated by the inhibition of PKCd and MEK-1/ERK. Our results suggest that a novel signaling pathway, GSK-3/PKCd/ERK/NF-kB, may play an important role in the regulation of COX-2 and IL-8 expression in colon cancer cells.
In conclusion, our results demonstrate that GSK-3 is an endogenous negative regulator of ERK. The contributions of MAPK/ERK, as well as those of PI3-kinase, to cell proliferation are widely accepted in a number of human cancers including colon cancer (Fernando and Wimalasena, 2004) . Therefore, our study provides a mechanism whereby the PI3-kinase pathway may converge and dictate the fate of colon cancer cells through GSK-3 inhibition-dependent ERK activation.
Materials and methods
Materials
Lithium chloride (LiCl) and rabbit anti-b-actin antibody were purchased from Sigma Chemical Company (St Louis, MO, USA). The GSK-3 inhibitors SB-216763 and SB-415286 were purchased from Tocris (Ellisville, MO, USA). The MEK-1 inhibitors U0126 and PD98059 were from Calbiochem (San Diego, CA, USA). GSK-3a, GSK-3b, PKCd and control siRNA were purchased from Dharmacon, Inc. (Lafayette, CO, USA). IL-8 promoter construct was a gift from Dr Allan R Brasier (UTMB, Galveston, TX, USA). COX-2 promoter construct was obtained from Dr Hiroyasu Inoue (Nara Women's University, Nara, Japan) (Inoue et al., 1994) . Mouse anti-GSK-3a/b antibody was from Upstate (Charlottesville, VA, USA). Rabbit anti-PKCd, mouse antiphosphorylated ERK1/2 and rabbit anti-ERK1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The human cell cytokine template set (hCK-5) was from BD Pharmingen (San Diego, CA, USA). (a-32 P) UTP (3000 Ci/ mmol) was from Amersham Pharmacia Biotech (Piscataway, NY, USA). Nitrocellulose filters for Northern blots were from Sartorius (Go¨ttingen, Germany). The constitutively expressed GAPDH gene was obtained from Ambion (Austin, TX, USA) and used to ensure the integrity of the RNA samples analyzed by Northern blot. Total RNA was isolated using Ultraspec RNA (Biotecx Laboratories, Houston, TX, USA). RNase protection experiments were performed using the RPA-III kit from Ambion. Polyvinylidene difluoride membranes for Western blots were purchased from Bio-Rad (Hercules, CA, USA), and X-ray film was purchased from Eastman Kodak (Rochester, NY, USA). The enhanced chemiluminescence system for Western immunoblot analysis was from Amersham (Arlington Heights, IL, USA). Tissue culture media was obtained from GIBCO-BRL (Grand Island, NY, USA). All other reagents were of molecular biology grade and purchased from either Sigma or Amresco (Solon, OH, USA).
Cell lines HT29 and Caco-2 (human colon cancer cell lines), PC-3 (human prostate cancer cell line), and 293 (human embryonic kidney cell line) were obtained from the American Type Culture Collection (ATCC). HT29 and Caco-2 were maintained in McCoy's 5A supplemented with 10% of fetal calf serum (FCS) and MEM supplemented with 15% of FCS, respectively. PC-3 cells were maintained in RPMI 1640 supplemented with 10% of FCS. 293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% of FCS.
Western blot analysis
Total protein (100 mg) was resolved on a 10% polyacrylamide gel and transferred to polyvinylidene difluoride membranes as previously described (Wang et al., 2000) . Filters were incubated for 1 h at room temperature in blotting solution. Membranes were incubated overnight with primary antibodies following blotting with a horseradish peroxidase-conjugated second antibody for 1 h and visualized using an enhanced chemiluminescence detection system. RNA isolation, Northern blot analysis and RNase protection assays Total RNA was isolated using the Ultraspect RNA reagent. RNA (30 mg) was run in 1.2% agarose/formaldehyde gels and transferred to supported nitrocellulose. Membranes were hybridized to a random-primed 32 P-labeled human COX-2 cDNA probe. After hybridization with the GAPDH probe, a control for equality of RNA loading, membranes were washed again and signals detected by autoradiography. RNase Protection Assay System was used for the detection of IL-8 mRNA as we have previously described (Wang et al., 2003) . 32 P-labeled antisense RNA probes were prepared and hybridization performed according to the manufacturer's protocol.
Cell transfections, luciferase assays
The GSK-3a, GSK-3b, PKCd and control siRNA duplexes and COX-2, IL-8 promoter reporter constructs were introduced into HT29 cells by electroporation (Gene Pulser, Bio-Rad). The pRL-Tk-luc plasmid was cotransfected to normalize for variation in transfection efficiency. At 48 h after transfection, the cells were rinsed with PBS, harvested and lysed with 1 Â cell culture lysis reagent. Luciferase activity in 20 ml of extract was assayed with the dual luciferase assay system. Light emissions were integrated for the initial 10 s of emission using a Monolight 2010 luminometer (Analytical Luminescence Laboratory).
PKCd kinase assay
PKCd activity was determined in cell extracts as described (Wang et al., 2003) . Briefly, total PKCd was determined by measuring the incorporation of 32 P into MBP. Cell extracts were incubated with PKCd antibody overnight and with protein A beads for 3 h at 41C by gentle rocking. Immunocomplexed beads were washed twice with cell lysis buffer and twice with kinase buffer (25 mM Tris, pH 7.4; 2 mM dithiothreitol; 0.1 mM Na 3 VO 4 ; 10mM MgCl 2 ; and 5 mCi of (g-32 P)ATP). Immunocomplexes were resuspended in 40 ml of kinase buffer supplemented with 10 mM ATP and 5 mg of MBP and incubated for 30 min at 301C. Kinase reactions were terminated with SDS sample buffer. Samples were sizefractionated by SDS-PAGE and 32 P-labeled MBP was quantified autoradiographically after fixing and drying the gel.
Abbreviations
GSK-3, glycogen-synthase kinase-3; COX-2, cyclooxygenase-2; ERK, extracellular signal-regulated kinase; LiCl, lithium chloride; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein.
